Physician profile

Michael E Herzog

Urology · Orland Park, IL

NPI 1639197957

$8,154.80

in general payments reported to CMS, 2019-2025

46 companies · $1,333 in 2025

The $1,333 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,150.62
Education$100.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Neotract INC. $1,489.07 2019-2020
Abbvie INC. $743.82 2022-2025
Sumitomo Pharma America, INC. $529.28 2023-2025 Gemtesa, Orgovyx
Teleflex LLC $520.42 2021-2025 Urolift, Barrigel
Astellas Pharma US INC $444.78 2019-2025 Xtandi, Myrbetriq
Allergan, INC. $405.63 2019-2022
Dendreon Pharmaceuticals LLC $381.55 2023-2025 Provenge
Calyxo, INC. $345.92 2024-2025 Cvac Aspiration System
Boston Scientific Corporation $254.10 2019-2025 Ams 700, Rezum Generator, Greenlight Xps
Janssen Biotech, INC. $247.22 2019-2025 Erleada
180 Medical, INC. $239.43 2022-2025
Antares Pharma, INC. $237.17 2019-2025 Xyosted
Axonics, INC. $216.71 2022-2024 Axonics, Bulkamid
Coloplast Corp $191.35 2024-2025
Laborie Medical Technologies Corp. $177.96 2023-2025 Optilume Bph Drug Coated Balloon Catheter
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Urovant Sciences INC $167.91 2021-2022
Srs Medical Systems, INC. $143.48 2021
Olympus America INC. $139.78 2020-2022
Medtronic, INC. $122.19 2023-2024 Interstim
Novartis Pharmaceuticals Corporation $113.24 2024
Bayer Healthcare Pharmaceuticals INC. $103.56 2022-2025
Tolmar, INC. $96.03 2023-2025 Jatenzo
Urogen Pharma, INC. $90.70 2023-2025 Jelmyto
Astrazeneca Pharmaceuticals LP $62.27 2023-2025 Imfinzi, Lynparza
Ferring Pharmaceuticals INC. $59.60 2024-2025 Adstiladrin
Accord Healthcare, INC. $56.88 2023-2024
Bioprotect Medical, INC. $54.47 2024-2025 Bioprotect Balloon Implant System
Merck Sharp & Dohme LLC $53.28 2022-2025 Keytruda
Myovant Sciences INC. $52.38 2021-2022
Endo USA, INC. $47.91 2024-2025 Xiaflex, Aveed
Myriad Genetic Laboratories, INC. $36.49 2022-2024 Prolaris
Blue Earth Diagnostics $35.96 2021-2022
Ambu INC. $32.04 2020
Rochester Medical Corporation $28.68 2021
Clarus Therapeutics INC. $25.24 2021
Genzyme Corporation $24.17 2022
Tolmar Pharmaceuticals, INC. $23.12 2019
Glaxosmithkline, LLC. $21.82 2023 Arexvy, Shingrix
Immunitybio, INC. $20.68 2025
Bluewind Medical $19.24 2024 Revi
Verity Pharmaceuticals INC. $19.02 2024 Trelstar
Pfizer INC. $18.08 2025
Cardinal Health 414 LLC $17.32 2023
C. R. Bard, INC. & Subsidiaries $15.82 2021
Halozyme INC $14.97 2023
Avation Medical, INC. $14.06 2025 Vivally System

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael E Herzog

$8,154.80

in general payments reported 2019-2025

Years
2019-2025
Top company
Neotract INC.
Context
The $1,333 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/300624/michael-e-herzog

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.